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1. General methods and materials for synthesis and materials for synthesis 
Chemicals were purchased from Sigma Aldrich, Alfa Aesar and Stream Chemicals and used without further 
purification. The removal of solvents under reduced pressure was carried outon a rotary evaporator Büchi 
R-210 equipped with a thermostated bath B-491, a vacuum regulator V-850, and a vacuum pump V-700. 
The solvents for organic synthesis were of reagent grade. Dry solvents were bought from Sigma-Aldrich. 
N,N-dimethylformamideand trifluoroacetic acid were purchased from Scharlau, dichloromethane from 
Panreac and acetonitrile from Merck. Water was deionized and purified on a Millipore Milli-Q Integral 
system. 
Chromatographic purification of products was accomplished using flash column chromatography on 
Merck Geduran Si 60 (40 – 63 μm) silica gel (normal phase) or by reversed-phase high-performance liquid 
chromatography (RP-HPLC) using H2O (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents and a Luna(C18)-
Phenomenex column. 
Thin layer chromatography (TLC) was performed on Merck 60 (silica gel F254) plates.  
1H-, 13C, DEPT and 31P NMR spectra were recorded in deuterated solvents (from Sigma-Aldrich and VWR) 
on a Bruker AMX 500 and Varian Mercury 300 spectrometers and calibrated to the residual solvent peak, 
if possible. The chemical shifts (d) are given in ppm, the coupling constants (J) in Hz. Multiplicities are 
abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad and com-
binations of these. 
Fluorescence measurements were performed in a Varian Cary Eclipse Fluorescence Spectrophotometer. 
Fluorescence microscopy images were obtained with an AndorZyla 4.2cameramounted on a Nikon Eclipse 
TiE microscope. Confocal images were acquired with a Andor DragonFly spinning disc confocal micro-
scope. 
Electrospray Ionization Mass Spectrometry (ESI/MS) was performed with a Bruker Amazon IT/MS using 
direct injection of a solution of the compound in dichloromethane into the MS. HRMS analysis were car-
ried out in a BRUKER AMAZON ETD. 
Catalysts Pd1-9 were kept stored at -32 °C as powder solids. For the catalytic studies the complexes were 
dissolved in DMSO in a concentration of 20 mM. These samples can be stored forat least 1 month without 
loss of activity.  
ABREVIATIONS: 
DMEM: Dulbecco's Modified Eagle Medium 
TMRE: Tetramethylrhodamine, ethyl ester (TMRE) 
FBS: Fetal bovine serum 





2. General synthetic procedure 
(2-Carboxyethyl)diphenyl(pyren-1-ylmethyl)phosphonium bromide (R3),1 Pd4,2 Pd6,3 1-ethyl-2,3,3-trime-
thyl-3H-indol-1-ium iodide (R4),4 4-(prop-2-yn-1-yloxy)benzaldehyde (R5a),4 (E)-2-(4-aminostyryl)-1-
ethyl-3,3-dimethyl-3H-indol-1-ium iodide (4),4 (E)-4-(3-(benzo[d]thiazol-2-yl)-2-(prop-2-yn-1-
yloxy)styryl)-1-methylpyridin-1-ium (5),5 diallyl(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-
diyl)dicarbamate (7)6 and 2-(3,6-bis(((prop-2-yn-1-yloxy)carbonyl)amino)-9H-xanthen-9-yl)benzoic acid 
(Rho-poc)7 were synthesized according to literature procedures. 
Ligands L1-L4, and compounds R1, R2, R5b, R6 and Pd2(Allyl)2Cl2 were purchased from Sigma-Aldrich, Alfa 
Aesar and Stream Chemicals. 
2.1 General synthetic procedure for Pd4-Pd7 
The catalyst Pd4 has been synthetized according to literature procedure.2 Pd2(Allyl)2Cl2 (100 mg, 0.273 
mmol) was dissolved in methylene chloride (4 mL) before pyridine (54 µL, 0.663 mmol) was added and 
the reaction was left stirring for 1 hour at room temperature. The solvent was removed under reduced 
pressure and the precipitate was washed with Et2O (3 x 5 mL) yielding an off yellow solid (110 mg, 64 %). 
To a 20 mM solution of either phosphine ligand L2-L4 (0.133 mmol, 2 eq.) in THF (3.3 mL), Pd2(Allyl)2Cl2 
was added (0.066 mmol, 1 eq.), and the mixture was stirred for 3 hours at room temperature under N2 
atmosphere. The crude resulting from evaporation of solvents was purified by flash chromatography on 
silica gel (EtOAc/Hex 2:1) yielding, after concentration, a pale yellow solid.3 
 
Figure S1. a) Representation of ligands L1-L4 and b) Representation of the reaction of L3 with Pd2(allyl)2Cl2 
























Pd4 (100 mg, 64 %)2 
1H NMR (500 MHz, CDCl3, rt) δ 8.83 (dt, J = 4.8, 1.7 Hz, 2H), 7.83 (tt, J = 7.8, 1.7 Hz, 1H), 7.44 – 7.37 (m, 
2H), 5.61 (m, 1H), 4.05 (bs, 2H), 3.13 (d, J = 7.5 Hz, 2H). 13C NMR (126 MHz, CDCl3, rt) δ 152.48 (CH), 138.03 
(CH), 125.08 (CH), 114.22 (CH), 63.42 (CH2), 59.04 (CH2). HRMS-ESI Calculated for [2M-Cl-]+ C16H20N2ClPd: 
488.8960; found: 488.9601. 1H NMR (500 MHz, CD2Cl2-d2, -60 °C) δ 8.76 – 8.70 (m, 2H), 7.82 (td, J = 7.7, 
1.8 Hz, 1H), 7.42 – 7.35 (m, 2H), 5.70 – 5.58 (m, 1H), 4.00 (dd, J = 6.9, 2.2 Hz, 1H), 3.92 – 3.86 (m, 1H), 3.23 
(d, J = 12.3 Hz, 1H), 2.92 (d, J = 12.2 Hz, 1H). 13C NMR (126 MHz, CD2Cl2-d2, -60 °C) δ 153.37 (CH), 139.23 
(CH), 126.16 (CH), 115.81 (CH), 65.76 (CH2), 58.71 (CH2). 
Pd5 (31 mg, 51 %) 
1H NMR (500 MHz, CDCl3) δ 6.69 (bs, 1H, NH), 5.53 (m, 1H), 4.42 (s, 1H), 4.20 (bs, 2H), 3.15 (d, J = 12.4 Hz, 
2H), 3.03 – 2.85 (m, 2H), 2.45 (s, 3H), 2.37 – 2.14 (m, 2H), 1.45 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 174.43 
(C), 155.90(C), 115.08 (CH), 80.50 (C), 65.38 (CH2), 53.07(CH2), 33.05 (CH2), 31.21 (CH2), 28.31 (CH3tBu), 
19.11 (CH3). HRMS-ESI Calculated for [M-Cl] + Na+ C13H23NNaO4PdS: 418.0275; found: 418.0340.  
Pd6 (36 mg, 74%)3 
1H NMR (300 MHz, CDCl3) δ 7.59 (m, 6H), 7.41 (m, 9H), 5.61 (m, 1H), 4.77 (m, 1H), 3.77 (m, 1H), 3.12 (m, 
1H), 2.84 (m, 1H). HRMS-ESI Calculated for [M-Cl]+ C21H20PPd: 409.0340; found: 409.0337. 
Pd7 (48 mg, 74 %) 
1H NMR (500 MHz, CDCl3) δ 8.13 – 8.10 (m, 1H, H), 8.10 – 8.06 (m, 1H, H), 7.78 – 7.71 (m, 2H), 7.71 – 7.65 
(m, 2H), 7.62 (m, 2H), 7.53 – 7.47 (m, 2H), 7.44 (m, 4H), 5.64 (m, 1H), 4.82 (t, 1H), 3.81 (dd, 1H), 3.20 – 
3.13 (m, 1H), 2.87 (d, 1H, H). 13C NMR (126 MHz, CDCl3) δ 177.02 (COOH), 139.29 (d, J = 38.3 Hz, C), 135.27 
(CH), 134.78 (CH), 134.28 (d, J = 12.9 Hz,CH), 133.89 (d, J = 12.9 Hz,CH), 131.63 (C), 131.29 (C), 131.19 
(CH), 131.04 (CH), 130.07 (d, J= 12.9 Hz, CH), 129.51 (CH), 128.97 (d, J = 10.4 Hz, CH), 128.54(CH), 118.44 
(CH), 80.46 (d, J = 30.3 HzCH), 61.55 (CH). 31P NMR (202 MHz, CDCl3) δ 21.89 (d, J= 127.2 Hz). HRMS-ESI 
Calculated for [M-Cl]+ C22H21PO2Pd: 453.0236; found: 453.0239. 
2.2 General synthetic procedure for the synthesis of Pd8 and Pd9 
The catalysts Pd8 and Pd9 were synthetized without isolation of the ligands L5 and L6, to avoid the oxida-
tion of the phosphine groups of the non-isolated ligands. Nevertheless, the formation of these ligands 





Figure S2. Representation of the ligands L5 and L6. 
 
Pd8 (40 mg, 15%) 
Carboxilic acid R1 (147 mg, 0.343 mmol, 1 eq.), HBTU (156 mg, 0.41 mmol, 1.2 eq.) and DIEA (182 mL, 
1.028 mmol, 3eq.) were added to a round bottom flask with 3.5 mL of DMF under N2 atmosphere, and 
then, R2 (100 mg, 0.411 mmol, 1.2 eq.) was added. The reaction mixture was stirred for 3 hours and 
diluted with THF (5.5 mL), before Pd2(allyl)2Cl2 (63 mg, 0.171 mmol, 0.5 eq.) was added. The mixture was 
stirred for another three hours at room temperature. The solvent was removed under reduced pressure 
and the crude purified by HPLC (55-95 % of CH3CN + 0.1% TFA in 30 min) yielding a pale yellow solid. (40 
mg, 15%). 
1H NMR (500 MHz, CD2Cl2) δ 7.85 (m, 2H), 7.74 – 7.61 (m, 12H), 7.49 (m, 1H), 7.42 (m, 2H), 7.33 (m, 4H), 
7.21 (m, 4H), 6.26 (t, J = 5.9 Hz, 1H, NH), 5.81 (m, 1H), 5.33 (s, 2H), 4.26 (m, 2H), 3.42 (m, 2H),3.15 (m, 4H), 
2.47 (t, J = 6.5 Hz, 2H), 2.05 – 1.88 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 171.85 (C), 135.98 (d, J = 3.0 Hz, 
CH), 134.03 (d, J = 9.9 Hz, CH), 132.82 (m, CH), 132.55 (d, J = 10.1 Hz, CH),131.66 (d, J = 5.6 Hz, CH), 131.15 
(d, J = 12.4 Hz, CH), 129.69 (m, CH), 129.20 (d, J = 12.1 Hz, CH), 123.51 (CH), 118.61 (C), 117.97 (C), 75.86 
(t, J = 15.3 Hz, CH2), 40.61 (m, CH2), 35.44 (d, J = 17.3 Hz, CH2), 26.21 (CH2), 22.17 (CH2), 19.10 (CH2). 31P 
NMR (202 MHz, CDCl3) δ 24.53 (P-Pd), 17.99 (P+Ph3), 143.09 (septet, 1JPF = 709.0 Hz, PF6-). HRMS-ESI 
Calculated for [M]+C40H43ClNOP2Pd: 756.1471; found: 756.1470; HRMS-ESI Calculated for [M-Cl]+ 
C40H43BrNOP2Pd: 802.1032; found: 802.0950. 
Pd9 (8 mg, 12%) 
Compound R3 (40 mg, 0.073 mmol, 1 eq.), HATU (33 mg, 0.87 mmol, 1.2 eq.) and DIEA (38 mL, 0.218 
mmol, 3eq.) were added to a round bottom flask with 1 mL of DMF under N2 atmosphere, and then R2 
(20 mg, 0.087 mmol, 1.2 eq.) was added. The reaction mixture was stirred for 1.5 hours and diluted with 
THF (5 mL), before Pd2(allyl)2Cl2 (15 mg, 0.042 mmol, 0.5 eq.) was added. The reaction was kept for an-
other three hours at room temperature. The solvent was removed under reduced pressure and the crude 
purified by HPLC (55-95 % of CH3CN + 0.1% TFA in 30 min) yielding a pale yellow solid (8 mg, 12%). 
1H NMR (500 MHz, CDCl3) δ 8.39 (s, 1H), 8.10 (d, J = 7.2 Hz, 1H), 7.98 – 7.89 (m, 2H), 7.81 (m, 2H), 7.74 – 
7.61 (m, 2H), 7.61 – 7.53 (m, 4H), 7.49 – 7.29 (m, 14H), 7.19 (m, 3H), 5.81 (m, 1H), 5.11 (d, J = 14.4 Hz, 2H), 

















(bs, 2H), 1.61 (bs, 2H). 13C NMR (126 MHz, CDCl3) δ 169.74 (CONH), 162.41 (q, J = 37.5 Hz, TFA), 135.19 
(CH), 133.86 (CH), 133.49 (CH), 132.30 (CH), 131.50 (C), 131.36 (CH), 131. 05 (C), 130.10 (d, J= 12.4, CH), 
129.30 (CH), 128.76 (CH), 128.26 (CH), 127.08 (CH), 126.45 (CH), 125.91 (CH), 125.70 (CH), 124.88 (CH), 
124.60 (C), 124.00 (C), 122.86 (CH), 121.59 (CH), 119.69 (C), 117.42 (C), 117.05 (C), 116.35 (C, TFA), 115.10 
(C), 112.78 (C), 75.65 (CH2), 40.41 (CH2), 27.80 (CH2), 26.95 (d, J = 46.4 Hz, CH2), 25.96 (CH2), 25.45 (CH2), 
17.50 (d, J = 52.9 Hz, CH2). 31P (202 MHz, CDCl3) 24.45 (s, Pd-P), 15.44 (P+Ph2Pyrene). HRMS-ESI calculated 
for [M]+ C50H47NOClP2Pd: 880.1856; found: 880.2820; HRMS-ESI calculated for [M-Cl]+ C50H46NOP2Pd: 
844.2102; found: 844.2100.   
 
Scheme S1. Reagents a) R1 (1 eq.), R2 (1.2 eq.), HBTU (1.2 eq.), DIEA (3 eq.), DMF (2 mL), 1h, RT; b) L5 (2.0 
eq), Pd2(Allyl)2Cl2 (1.0 eq), N2, RT, 3 hours; c) R3 (1 eq.), R2 (1.2 eq.), HATU (1.2 eq.), DIEA (3 eq.), DMF (2 
mL), 1h, RT; d) L6 (2.0 eq), Pd2(Allyl)2Cl2 (1.0 eq), N2, RT, 3 hours 
2.2.1 HR-ESI-MS spectra of the complexes 
 




























































































Figure S4. Experimental (top) and calculated (bottom) HR-ESI-MS of Pd7 (left), Pd8 (middle) and Pd9 
(right).  
2.2.2 Spectroscopic studies of Pd9 
For the spectroscopic studies a fresh solution of the metal complex (10 mM in DMSO) was prepared and 
diluted into a quartz Hellma® fluorescence cuvette with a path-length 35x10 mm, chamber volume 3.5 
mL to reduce the complex concentration to 1 µM in methanol. The samples were analyzed in a Jasco V-
630 UV-Vis spectrophotometer and in a Varian Cary Eclipse Fluorescence Spectrophotometer. Samples 
were recorded at 25 °C. UV-Vis analyses were performed in the interval of 250-600 nm (Figure S5). For 
the fluorescence studies, Pd9 was excited at 345 nm and the emission spectrum was recorded in the 
interval 350-600 nm. The excitation fluorescence spectra of Pd9 was recorded in the interval 250-355 nm 
with λem380 nm.  
 




2.3 Procedure for the synthesis of 1, 2 and 3 
 
Scheme S2. General scheme for the synthesis of probes 1 and 2. 
2.3.1 (E)-1-ethyl-3,3-dimethyl-2-(4-(prop-2-yn-1-yloxy)styryl)-3H-indol-1-ium iodide (1) 
1-Ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide (R4, 100 mg, 0.317 mmol, 1eq.) was dissolved in ethanol (3 
mL), and piperidine (0.006 mL, 0.063 mmol, 0.2eq.) was added to give an orange solution. 4-(prop-2-yn-
1-yloxy)benzaldehyde (R5a, 55.9 mg, 0.349 mmol, 1.1 eq.) was added and the colour of the solution 
changed to red. The reaction was stirred under reflux until the consumption of the imidazolinium, moni-
tored by TLC (12h). The reaction mixture was allowed to cool down to rt, and the residue was purified by 
flash column chromatography using CH2Cl2:MeOH (98:2) to afford(E)-1-ethyl-3,3-dimethyl-2-(4-(prop-2-
yn-1-yloxy)styryl)-3H-indol-1-ium iodide (1) (90.0 mg, 0.197 mmol, 62.0%) as a brown solid, Rf = 0.5, 
MeOH: CH2Cl2 (5:95). 1H NMR (500 MHz, CDCl3) δ 8.16 (d, J = 15.0 Hz, 1H), 7.98 (d, J = 7.9 Hz, 2H), 7.62 – 
7.53 (m, 5H), 7.14 (d, J = 7.1 Hz, 2H), 4.82 (d, J = 2.4 Hz, 2H), 4.74 (s, 1H), 2.68 (s, 1H), 2.60 (t, J = 2.3 Hz, 
1H), 1.82 (s, 5H). 13C NMR (126 MHz, CDCl3) δ 181.14 (C), 163.13(C), 155.22 (CH), 143.23 (C), 140.40 (C), 
133.49 (CH), 129.90 (CH), 129.85 (CH), 127.50(C), 122.81(CH), 116.38 (CH), 114.52 (CH), 109.87 (CH),76.79 
(CH), 56.36 (CH2), 52.36 (C), 42.90 (CH2), 27.19 (CH3), 13.85 (CH3). LRMS (m/z, ESI): 330.18 (M+), 315.16, 
276.14. HRMS-ESI Calculated for C23H24NO: 330.1852, found 330.1852. 
2.3.2 (E)-1-ethyl-2-(4-hydroxystyryl)-3,3-dimethyl-3H-indol-1-ium iodide (2) 
1-Ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide (R4, 200 mg, 0.635 mmol, 1 eq.) was dissolved in ethanol (6 
mL), and piperidine (0.013 mL, 0.127 mmol, 0.2 eq.) was added, forming an orange solution. After that 4-
hydroxybenzaldehyde R5b (77.5 mg, 0.635 mmol, 1 eq.) was added and the colour of the solution changed 
to red. The reaction was stirred under reflux until the consumption of the starting material asmonitored 
by TLC and RP-HPLC (12h). The reaction mixture was allowed to cool down to rt and the crude residuewas 
purified by flash column chromatography using CH2Cl2:MeOH (98:2 to 90:10) to afford(E)-1-ethyl-2-(4-
hydroxystyryl)-3,3-dimethyl-3H-indol-1-ium iodide (2) (200.0 mg, 0.477 mmol, 75%) as a red solid. Rf = 
0.59, MeOH:CH2Cl2 (10:90).  
1H NMR (500 MHz, Methanol-d4) δ 8.41 (d, J = 16.0 Hz, 1H), 8.02 – 7.97 (m, 2H), 7.78 – 7.72 (m, 2H), 7.65 
– 7.57 (m, 2H), 7.43 (d, J = 16.1 Hz, 1H), 7.00 – 6.94 (m, 2H), 4.65 (q, J = 7.3 Hz, 2H), 1.83 (s, 6H), 1.56 (t, J 
= 7.3 Hz, 3H). 13C NMR (126 MHz, Methanol-d4) δ 182.83 (C), 165.56 (C), 157.05 (CH), 144.85 (C), 141.86 


























53.49 (C), 42.92 (CH2), 26.80 (CH3), 13.77 (CH3). LRMS (m/z, ESI): 292.17 (M+), 277.15. HRMS-ESI Calculated 
for C20H22NO (M+): 292.1696, found 292.1695. 
2.3.3 (E)-2-(4-(((allyloxy)carbonyl)amino)styryl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium (3) 
 
(E)-2-(4-aminostyryl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide (4, 100.0 mg, 0.239 mmol, 1 eq.) was 
dissolved in dry CH2Cl2 (5 mL). Pyridine (0.038 mL, 0.478 mmol. 2 eq.) was added, and a CH2Cl2 (1 mL) 
solution of Alloc-Cl (R6, 0.052 mL, 0.478 mmol, 2 eq.) was added dropwise at 0ºC. The reaction mixture 
was warmed at rt and stirred overnight. After complete consumption of the starting material, the reaction 
was washed with a saturated solution of NaHCO3 (10 mL), extracted with CH2Cl2 (2 x 10 mL), dried over 
Na2SO4 and purified by flash column chromatography using MeOH:Hexanes:CH2Cl2 (0.5:1:8.5)to givethe 
product(E)-2-(4-(((allyloxy)carbonyl)amino)styryl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium (3,110 mg, 0.219 
mmol, 91%) as a red crystalline solid. Rf = 0.41, MeOH:Hexanes:CH2Cl2 (1:1:8). 
1HNMR (300 MHz, Methanol-d4) δ 8.43 (d, J = 16.2 Hz, 1H), 8.06 (d, J = 9.0 Hz, 2H), 7.92 – 7.48 (m, 7H), 
6.10 – 5.94 (m, 1H), 5.56 – 5.21 (m, 2H), 4.75 – 4.64 (m, 4H), 1.85 (s, 6H), 1.58 (t, J = 7.4 Hz, 3H).13C NMR 
(75 MHz, Methanol-d4) δ 182.90 (C), 156.08 (CH), 154.89 (C), 146.31 (C), 145.08 (C), 141.82 (C), 133.85 
(C), 133.52 (CH), 130.65 (CH), 130.55(CH), 129.96(C), 124.12(CH), 119.53(CH), 118.25 (C), 115.80 (CH), 
110.73 (CH), 66.80 (CH2), 53.71 (C), 49.00 (CH2), 43.57 (CH2), 26.79 (CH3), 14.16 (CH3).HRMS-ESI Calculated 
for C24H27N2O2: 375.2067, found 375.2062. 
3. Catalysis experiments in vitro 
For the in vitro experiments with complexes Pd1-9, we used the propargylated phenol probe 1 and the 
alloc protected aniline 3, as they allow an easy monitoring of the reaction by RP-HPLC-MS. For RP-HPLC 
analysis H2O + 0.1% TFA and CH3CN + 0.1% TFA were used as eluents in a 5-95 % gradient ofCH3CN + 0.1% 
TFA in 11.6 minutes using a Phenomenex Kinetex XB-C18: 1.7 µm, 100 Å, 2.1 x 50 mm column. 
The palladium complexes added to the cells were initially dissolved in DMSO (20 mM) before being added 
to the reaction media, so the final concentration of DMSO in DMEM is minimal (< 0.1%). 
Cell Lysate preparation  
For the preparation of the HeLa cells lysates, 3x106 exponentially growing Hela cells were washed twice 
with PBS, scrapped with a rubber policeman in 0,5 mL of PBS and sonicated intensely for 2 rounds of 1 
min with a 30 second cooling period in between. The protein concentration of the lysates was quantified 
by DCTM Protein Assay (BioRad) and equalised to 1 mg ml-1 for reproducibility among experiments. 
N NH+
DCM















3.1 Calibration curve and RP-HPLC-MS characterization of compounds 1-4 
 
Figure S6. RP-HPLC-MS chromatogram (left) and ESI-MS spectra (right) for compound 1. 
 
Figure S7. RP-HPLC-MS chromatogram (left) and ESI-MS spectra (right) for compound 2. 
 
Figure S8. RP-HPLC-MS chromatogram (left) and calibration curve (right) for compound 2. I.S.= internal 
standard. 


















































































) R2 = 0.9987
y = 0.004512*X - 0.003174
Linear regression
































Figure S9. RP-HPLC-MS chromatogram (left) and ESI-MS spectra (right) for compound 4. 
 
Figure S10. RP-HPLC-MS chromatogram (left) and calibration curve (right) for compound 4. 
 
Figure S11. RP-HPLC-MS chromatogram (left) and ESI-MS spectra (right) for compound 3. 
3.2 Uncaging of probe 1 
 
The catalytic deprotection of 1 to release the uncaged product 2, under biologically relevant conditions, 
was performed in a 2.0 mL HPLC-vial with screw cap. For this purpose, fresh solutions of 1 (10 µL, 20 mM 


















































































y = 0.004979*X + 0.0119
Linear regression















































in DMSO, 1.0 eq) were either added to water, PBS or HeLa cell lysates (990 µL), and to the resulting mix-
ture was added a solution of the palladium complex (1 µL, 20 mM in DMSO, 0.1eq). The reaction mixture 
was kept for 24 h at 37 °C under stirring at 1000 rpm. At regular intervals, aliquots of the reaction (50 µL 
and diluted to 100 µL with MeOH) were analyzed by RP-HPLC-MS. The results were treated according to 
the previous calibration curve, in which coumarin was used as internal standard. Every value is the average 
value of two independent measurements. 
3.3 Uncaging of probe 3 
 
The catalytic deprotection of 3 to release the uncaged amine 4, under biologically relevant conditions, 
was performed in a 2.0 mL HPLC-vial with screw cap. For this purpose, fresh solutions of 3 (4 µL, 50 mM 
in DMSO, 1.0 eq) were either added to water, GSH (0.4 mM in 1 mL of H2O) or sodium ascorbate (2 mM) 
solutions (996 µL) before a solution of the catalyst (1 µL, 20 mM in DMSO, 0.1 eq) was added. The reaction 
mixture kept for 24 h at 37 °C under stirring at 1000 rpm. At regular intervals (1, 3, 6 and 24 hours), 
aliquots of the reaction (50 µL and diluted to 100 µL with MeOH) were analyzed by RP-HPLC-MS. The 
results were treated according to a previous calibration, in which coumarin was used as internal standard. 
Every value is the average value of two independent measurements. 
4. Cell culture experiments 
All cell lines were cultured in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% (v/v) 
fetal bovine serum (FBS), 5 mM glutamine, penicillin (100 units/mL) and streptomycin (100 units/mL) (all 
from Invitrogen). Proliferating cell cultures were maintained in a 5% CO2 humidified incubator at 37 °C.  
4.1 ICP-MS analysis 
For the ICP measurements, 150000 Vero cells per well were seeded in 6 well plates one day before treat-
ment with the Pd complexes (50 µM) in DMEM-FBS for 30 minutes. Cells were then washed twice with 
PBS and lysed in 70% HNO3. The obtained lysates were digested in duplicate with HNO3 / H2O2 by heating 
with microwave energy before being analyzed.  
For the ICP measurements of mitochondrial fractions, Vero cells were treated with 50 μM of the different 
catalysts in DMEM-FBS for 60 minutes. Then, a commercial kit (Mitochondria Isolation Kit -Thermo-Fisher 
Scientific) was used to isolate mitochondrial and cytosolic cellular fractions. The fractions obtained were 

















Figure S12. ICP-MS measurements of palladium content in Vero cells incubated with different palladium 
complexes, after washing and lytic treatment. The analysis reflects all palladium accumulated in different 
parts of the cell. Error bars represent the standard error of three independent experiments.  
 
 
Figure S13. ICP-MS results of the Pd6-9 accumulated in living cells and the fractioning of their accumula-
tion in cytosol and mitochondria in % distribution.  
4.2 Viability Assays 
The toxicity of the catalysts Pd1-Pd9 was tested by MTT assays in Vero cells as follows: 75000 cells per 
well were seeded in 96 well plates one day before treatment with different concentrations of the cata-
lysts. After 24 h of incubation, Thiazolyl Blue Tetrazolium Bromide (Sigma) was added to the cell culture 
medium to a final concentration of 0.5 mg/ml. Cells were then incubated for 4 h to allow the formation 
of formazan precipitates by metabolically active cells. A detergent solution of 10% SDS (sodium dodecyl 
sulphate) and 0.01 M HCl was then added and the plate was incubated overnight at room temperature to 




the number of viable cells) was measured by recording changes in absorbance at 570 nm in a microtiter 
plate reading spectrophotometer (Tecan Infinite 200 PRO). 
 
Figure S14. Viability Assays. Vero cells were incubated in cell culture medium containing the indicated 
amounts of the catalysts Pd1-9 for 24 h and analysed by MTT assay. The viability is expressed as the fold 
change of the absorbance value with respect to untreated cells (value 1.0). Error bars indicate the stand-
ard deviation of three independent experiments. 
4.3 Reactions in living cells 
Probes 5 and 7 were selected because the released products 6 and 8 possess optimal photophysical prop-
erties for the microscopy imaging of the cellular experiments, both for uncaging of the propargyl5 and 
alloc6 groups, respectively. 
The palladium complexes added to the cells were initially dissolved in DMSO (20 mM) before being added 
to DMEM, so the final concentration of DMSO in DMEM is minimal (<0.5%). 
Microscopy settings: Widefield micrographs were taken with a Nikon Eclipse TiE equipped with an An-
dorZyla 4.2 camera. Confocal images were acquired in an Andor Dragonfly High Speed Confocal Platform. 
The filter sets for the observation of the different fluorophores were as follows:  
Pd9: Widefield: LED λ excitation: 385 nm. Filter cube DAPI-1160B-000 (Semrock): BP 387/11-25 nm, LP 
447/60-25 nm and DM 409 nm. Confocal: Laser excitation: 405 nm. LP 450/50 and DM 418 nm. 
6: Widefield: LED λ excitation: 385 nm. Filter cube: BP 375/28x nm, LP 515lp nm and DM 415 nm.  
8: Widefield: LED λ excitation: 470 nm. Filter cube FITC-3540C-000 (Semrock): BP 482/35 nm, LP 536/40 
nm and DM 506 nm. Confocal: Laser excitation: 488 nm. LP 525/50 and DM 501 nm. 
TMRE (tetramethylrhodamine, ethyl ester) LED λ excitation: 550 nm. Filter cube TRITC-B-000 (Semrock): 
BP 543/22-25 nm, LP 593/40-25 nm and DM 562 nm. Confocal: Laser excitation: 561 nm. LP 620/60 and 





Unless otherwise indicated, all incubations were made in a humidified incubator at 37°C in an atmosphere 
containing 5% CO2: 
Preincubation with the probes: Vero or HeLa cells were seeded on glass coverslips 24h before incubation. 
Culture medium was removed and DMEM containing 5% fetal bovine serum (FBS-DMEM) and probes 5 
(50 µM) or 7 (100 µM) were added. After a 30-minute incubation, cells were washed twice with FBS-
DMEM and 50 µM of a solution of metal complexes in FBS-DMEM were added. After a 30-minute incuba-
tion, cells were washed twice in FBS-DMEM, and observed in a widefield fluorescence microscope with 
adequate filters. 
Preincubation with the metal complexes: Vero or HeLa cells were seeded on glass coverslips 24h before 
incubation. Culture medium was removed and 50 µM of the palladium complexes in FBS-DMEM were 
added. After 30-minute incubation, cells were washed twice with FBS-DMEM, and FBS-DMEM containing 
5 (50 µM) or 7 (100 µM) was added. After a 30-minute incubation, cells were washed twice in FBS-DMEM, 
and observed in a widefield fluorescence microscope with adequate filters.  
Digital pictures of the different samples were taken under identical conditions of gain and exposure. 
4.3.1 Uncaging of propargylic probe 5 
Note: There is an overlap between the excitation wave length of probe 6 and that of the pyrene moiety 







Figure S15. Imaging of the uncaging of 5 in Vero cells with complexes a) Pd1; b) Pd2, c) Pd3, d) Pd4, e) 
Pd5, and f) control without palladium complexes. Reaction conditions: 5 (50 µM) was incubated in DMEM 
with 5% Fetal Bovine Serum for 30 min before the Pd complex (50 µM) was added, and the cells were 
incubated for another 30 min (Scale bar = 20 µm). 
Estimation of TON 
For the estimation of the TON of the uncaging reaction using probe 5, 500.000 HeLa cells growing in six-
well plates were incubated with probe 5 (50 µM) for 30 minutes followed by incubation with Pd catalysts 
Pd6-9 (50 µM) for another 30 minutes. Afterwards, the cells were washed twice with PBS and the cell 
monolayer was treated with 200 µL of 80% MeOH in water. This methanol extract was recovered and 
measured in a Varian Cary Eclipse Fluorimeter in a quartz Hellma® fluorescence cuvette with a path length 
10 x 4 mm, chamber volume 1.4 mL, exciting at 385 nm and recording the emission spectra between 500-
750 nm. For the determination of the concentration, we used a fluorescence calibration curve for 6 [y= 
138.2 (1) x + 2 (4)].  
Using the resulting concentration data and considering the amount of intracellular Pd as calculated by 
ICP-Ms, we could obtain an average TON from two repetitions. It is important to note that the protocol 





Figure S16. Fluorescence emission calibration curve for compound 6. 
 
Figure S17. Imaging of the uncaging of probe 5 in HeLa cells with different palladium reagents a) Pd1; b) 
Pd2, c) Pd3, d) Pd4, e) Pd5, f) Pd6, g) Pd7, h) Pd8 and i) control without palladium. In contrast to that 
observed with Vero cells, catalyst Pd8 elicited higher intracellular fluorescence than Pd7. Reaction condi-
tions: 5 (50 µM) was added to the cells in DMEM with 5% Fetal Bovine Serum, and incubated for 30 min, 
after standard washing with DMEM, cells were mixed with the Pd complexes (50 µM) for other 30 min 




4.3.2 Uncaging of alloc probe 7 
• Cellular activity of the palladium complexes in HeLa cells: 
 
Figure S18. Comparative micrographies obtained after the Pd catalysed uncaging of 7 in HeLa cells with 
catalysts a) Pd1, b) Pd2, c) Pd3, d) Pd4, e) Pd5, f) Pd6, g) Pd7, h) Pd8, and i) control. Reaction conditions: 
probe 7 (50 µM) was incubated in DMEM with 5% Fetal Bovine Serum for 30 min. After standard washing, 
the Pd complexes (50 µM) were added, and the cells further incubated for another 30 min, and visualized 
(Scale bar = 20 µm).  
 
Figure S19. Fluorescence micrographies obtained using palladium complex Pd8 for the uncaging of Rho-
alloc 7 in HeLa cells; i) Green channel; ii) merge of green channel with brightfield; iii) mock (green channel) 
and iv) merge of mock with brightfield. Reaction conditions: Pd8 (50 µM) was incubated with cells in 
DMEM with 5% Fetal Bovine Serum for 30 min. After standard washing, probe 7 (50 µM) was added and 





Figure S20. Fluorescence micrographies for the Pd-promoted uncaging of 7 in Vero cells with different 
palladium complexes: a) control, b) Pd4, c) Pd7 and d) Pd8. Reaction conditions: Pd8 (50 µM) was incu-
bated with cells in DMEM with 5% Fetal Bovine Serum for 30 min. After standard washing, probe 7 (50 
µM) was added and the cells were incubated for another 30 min and visualized (Scale = 20 µm). 
Intracellular localization with Pd8 and Pd9 
Cells growing on glass coverslips were incubated with the Pd complexes (50 µM) for 2 hours. Cells were 
then washed twice with FBS-DMEM and incubated with the probe 7 (100 µM) in FBS-DMEM for 30 
minutes. Finally, the mitochondrial marker TMRE was added in FBS-DMEM to a final concentration of 100 
nM and cells incubated for 10 min. Prior to the observation by fluorescence microscopy, the samples were 
washed twice with fresh FBS-DMEM. For a better determination of the degree of colocalization, the co-
verslips were observed in vivo in a confocal microscope equipped with adequate filters. Digital pictures of 







Figure S21. Imaging of the Pd catalyzed uncaging of 7 in HeLa cells preincubated with complexes Pd9 (a1-
f1), Pd8 (a2-f2) and control without palladium (a3-f3) and stained with the mitochondrial marker TMRE. 
a1-a3) TMRE, b1-b3) green fluorescence resulting from the formation of uncaged probe 8, c1-c3) blue 
fluorescence of the pyrene moiety present in Pd9, d1-d3) merge of blue and green channels, e1-e3) merge 
of red and green, f1-f3) merge of all three channels (Scale bar = 20 µm). 
4.3.3 Uncaging of Rho-poc 
HeLa cells were seeded on glass coverslips 24h before incubation. Culture medium was removed and 50 
µM of the palladium complexes in FBS-DMEM were added. After a 30-minute incubation, cells were 
washed twice with FBS-DMEM, and FBS-DMEM containing Rho-poc (50 µM) was added. After a 30-minute 








Figure S22. Imaging of the Pd catalyzed uncaging of Rho-poc in HeLa cells: control without palladium (a1-
a5); preincubated with complexes Pd8 (b1-b5) and Pd9 (c1-c5); (a2-c2) green fluorescence that is coming 
from uncaged Rho-poc, (a1-c1) blue fluorescence of the pyrene moiety present in Pd9 (c1), (a4-c4) bright-
field-green channel merging, (a5-c5) merge of brightfield, blue and green channels. (Scale bar = 25 µm). 
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Low Temperature spectra (- 60°C) 
 
  
N
Cl
Pd
Pd4
 
 
28 
 
  
Pd5
S
O OH
N
H
O
O Cl
Pd
 
 
29 
P
Ph
Ph
Pd
Cl
Pd7
HO
O
 
  
 
 
30 
Pd8
Ph
Ph
P
H
N
O
P
Ph
Ph
Ph
PF6 Pd
Cl
 
 
 
31 
 
 
  
Pd9
Ph
PhP
H
NTFA
O
P
PhPh
Pd
Cl
 
 
32 
Ph P
Ph
Ph
Pd
Cl
Pd6
 
 
